We purified primary leukemia blasts from five human AML patients, including samples with FLT3, NPM1 and IDH1 mutations, and cultured them ex vivo24, followed by treatment with either DMSO or mebendazole (1 μM) for a week. This evidence concerns the gene IDH1 and acute myeloid leukemia.